Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Multicenter Phase II Clinical Study of Recombinant Humanized Anti-CD47 / PD-1 Bifunctional Antibody HX009 Injection in the Treatment of Advanced Solid Tumors

NCT04886271 is registered in ClinicalTrials.gov with Hangzhou Hanx Biopharmaceuticals, Ltd. as lead sponsor.

NCT NCT04886271
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04886271 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Multicenter Phase II Clinical Study of Recombinant Humanized Anti-CD47 / PD-1 Bifunctional Antibody HX009 Injection in the Treatment of Advanced Solid Tumors
Lead sponsor
Hangzhou Hanx Biopharmaceuticals, Ltd.
Phase
Phase 2
Overall status
Completed
Start date
May 12, 2021
Completion date
February 22, 2024
Enrollment
20 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

advanced solid tumor